Otago to evaluate Ginexid for the UK market

Otago Healthcare has signed an exclusive agreement with Bologna based Farma Derma to discuss the marketing of one of its key products Ginexid. In this agreement Otago will have exclusivity for a period of 9 months to discuss the product for full commercialisation with key buyers in the retail pharmacy sector.

Sanjeev Pooni, CEO commented:-

we have a very strong relationship with Farma Derma where we have launched other brands for them in the UK. We are very excited about them giving us the opportunity in this first instance to speak and meet with our key contacts to see how we commercialise the product cost effectively and profitability